ClinicalTrials.gg
RecruitingNCT07606066Updated Aug 25, 2026

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

An observational study in Type 2 Diabetes, sponsored by AstraZeneca. Recruiting at 76 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by AstraZeneca · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.

Planned enrollment
32nd of 65
2,150 · median 2,000
Started
2026
with 13 others
Observational
65 of 345
2 open now
Primary completion
2027-03
later than 4 of 14 live
Registered
335th of 345
by date

Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 32nd largest by planned enrollment of the 65 observational ones that give a count, is one of 14 that started in 2026, is one of 65 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 335th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with Type 2 Diabetes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥ 18 years of age at the time of signing the ICF.
  • Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World

Health Organization or local diagnostic standards, inadequately managed with:

  1. Lifestyle management alone, AND/OR
  2. A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF.

    • Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required.
    • Provision of signed and dated written (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.

Exclusion criteria

Exclusion Criteria:

  • Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of GLP-1 RAs (As specified in the Protocol).
  • Diagnosed with Type 1 diabetes mellitus.
  • Known pregnancy at the time of visit or having the intention to become pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,150 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Participants with Type 2 Diabetes

    Participants with Type 2 Diabetes

    Other: Procedure: assessment

Interventions

  • OtherProcedure: assessment

    The approximate volume of blood required is 2 mL

06

What researchers measure

Primary outcomes

  1. Patient demographics

    Summary statistics

    Time frame: Visit 1 (Single day)

  2. Medical and surgical history

    Summary statistics

    Time frame: Visit 1 (Single day)

  3. Concomitant medication

    Summary statistics

    Time frame: Visit 1 (Single day)

  4. HbA1c levels

    Summary statistics

    Time frame: Visit 1 (Single day)

Secondary outcomes

  1. Referral to ongoing or future T2DM study.

    Number of participants with high likelihood of meeting eligibility criteria in ongoing or future T2DM studies, for referral to those studies.

    Time frame: Visit 1 (Single day)

07

Study locations

19 of 76 sites recruiting
  • Research Site
    Peoria, Arizona 85382, United States
    Not yet recruiting
  • Research Site
    Little Rock, Arkansas 72205, United States
    Recruiting
  • Research Site
    Lincoln, California 95648, United States
    Recruiting
  • Research Site
    Jacksonville, Florida 32256, United States
    Not yet recruiting
  • Research Site
    Lake City, Florida 32055, United States
    Recruiting
  • Research Site
    Leesburg, Florida 34748, United States
    Not yet recruiting
  • Research Site
    Ocoee, Florida 34761, United States
    Recruiting
  • Research Site
    Decatur, Georgia 30030, United States
    Recruiting
  • Research Site
    Melrose Park, Illinois 60160, United States
    Not yet recruiting
  • Research Site
    El Dorado, Kansas 67042, United States
    Not yet recruiting
  • Research Site
    Potomac, Maryland 20854, United States
    Recruiting
  • Research Site
    Maumee, Ohio 43537, United States
    Not yet recruiting
  • Research Site
    Gaffney, South Carolina 29340, United States
    Recruiting
  • Research Site
    Renton, Washington 98057, United States
    Recruiting
  • Research Site
    Fortaleza, Ceará 60430-350, Brazil
    Not yet recruiting
  • Research Site
    Curitiba, Paraná 80030-480, Brazil
    Recruiting
  • Research Site
    Natal, Rio Grande do Norte 59020-035, Brazil
    Not yet recruiting
  • Research Site
    Porto Alegre, Rio Grande do Sul 90630-165, Brazil
    Not yet recruiting
  • Research Site
    Campinas, São Paulo 13060-904, Brazil
    Not yet recruiting
  • Research Site
    São José dos Campos, São Paulo 12243-280, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, São Paulo 01228-200, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, São Paulo 04012-180, Brazil
    Not yet recruiting
  • Research Site
    Barretos, 14784-400, Brazil
    Not yet recruiting
  • Research Site
    Brasília, 71625-009, Brazil
    Not yet recruiting
  • Research Site
    Rio de Janeiro, 22270-060, Brazil
    Not yet recruiting
  • Research Site
    Budapest, HU 1036, Hungary
    Recruiting
  • Research Site
    Budapest, HU 1089, Hungary
    Recruiting
  • Research Site
    Debrecen, HU 4032, Hungary
    Not yet recruiting
  • Research Site
    Szeged, HU 6725, Hungary
    Not yet recruiting
  • Research Site
    Budapest, 1024, Hungary
    Recruiting
  • Research Site
    Budapest, 1132, Hungary
    Recruiting
  • Research Site
    Budapest, 1138, Hungary
    Not yet recruiting
  • Research Site
    Salgótarján, 3100, Hungary
    Not yet recruiting
  • Research Site
    Szolnok, 5000, Hungary
    Not yet recruiting
  • Research Site
    Zalaegerszeg, 8900, Hungary
    Recruiting
  • Research Site
    Guntur, Andhra Pradesh 522001, India
    Not yet recruiting
  • Research Site
    Guwahati, Assam 781032, India
    Not yet recruiting
  • Research Site
    Bangalore, Karnataka 560092, India
    Not yet recruiting
  • Research Site
    Belagavi, Karnataka 590006, India
    Not yet recruiting
  • Research Site
    Belagavi, Karnataka 590010, India
    Not yet recruiting
  • Research Site
    Calicut, Kerala 673008, India
    Not yet recruiting
  • Research Site
    Kochi, Kerala 682041, India
    Not yet recruiting
  • Research Site
    Thiruvananthapuram, Kerala 695031, India
    Not yet recruiting
  • Research Site
    Indore, Madhya Pradesh 452008, India
    Not yet recruiting
  • Research Site
    Mumbai, Maharashtra 400012, India
    Not yet recruiting
  • Research Site
    Nagpur, Maharashtra 440010, India
    Not yet recruiting
  • Research Site
    Pune, Maharashtra 411013, India
    Not yet recruiting
  • Research Site
    Pune, Maharashtra 411021, India
    Not yet recruiting
  • Research Site
    Delhi, New Delhi 110029, India
    Not yet recruiting
  • Research Site
    Jaipur, Rajasthan 302017, India
    Not yet recruiting
  • Research Site
    Chennai, Tamil Nadu 600086, India
    Not yet recruiting
  • Research Site
    Coimbatore, Tamil Nadu 641018, India
    Not yet recruiting
  • Research Site
    Lucknow, Uttar Pradesh 226030, India
    Not yet recruiting
  • Research Site
    Kolkata, West Bengal 700020, India
    Not yet recruiting
  • Research Site
    Seremban, Negeri Sembilan 70300, Malaysia
    Recruiting
  • Research Site
    Seri Manjung, Perak 32040, Malaysia
    Not yet recruiting
  • Research Site
    Batu Caves, Selangor 68100, Malaysia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Kuala Lumpur, Wilayah Persekutuan Kuala Lump 59100, Malaysia
    Not yet recruiting
  • Research Site
    Putrajaya, 62250, Malaysia
    Not yet recruiting
  • Research Site
    Lublin, Lublin Voivodeship 20-718, Poland
    Not yet recruiting
  • Research Site
    Krakow, Malopolska 31-261, Poland
    Not yet recruiting
  • Research Site
    Radom, Masovian Voivodeship 26-600, Poland
    Not yet recruiting
  • Research Site
    Bialystok, Podlaskie Voivodeship 15-879, Poland
    Recruiting
  • Research Site
    Częstochowa, Silesian Voivodeship 42-217, Poland
    Not yet recruiting
  • Research Site
    Poznan, 60-354, Poland
    Recruiting
  • Research Site
    Warsaw, 00-124, Poland
    Not yet recruiting
  • Research Site
    Lodz, Łódź Voivodeship 90-338, Poland
    Recruiting
  • Research Site
    Kielce, Świętokrzyskie Voivodeship 25-355, Poland
    Not yet recruiting
  • Research Site
    Ankara, Turkey 6100, Turkey (Türkiye)
    Recruiting
  • Research Site
    Adana, 01060, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Adana, 01250, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Ankara, 06530, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Gaziantep, 27470, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Istanbul, 34265, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Istanbul, 34384, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Kayseri, 38039, Turkey (Türkiye)
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Mar 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2026
First posted
May 26, 2026
StartActual
May 6, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07606066
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
May 26, 2026
Start date
May 6, 2026
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Aug 25, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion